Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02514525 · ClinicalTrials.gov registry record · NA

Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System

A NA study of Barrett Esophagus, sponsored by Pentax Medical.

Active
Registry status
NA
Development phase
150
Enrollment target
11
Study locations

NCT02514525: Active NA study of Barrett Esophagus, sponsored by Pentax Medical.

NCT02514525 is a NA study of Barrett Esophagus that is active but no longer recruiting, run by Pentax Medical. The registered enrollment target is 150 participants, below the 3,561-participant average among 32 other Barrett Esophagus trials with a reported enrollment target (96% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02514525, a NA study of Barrett Esophagus, is active but no longer recruiting, sponsored by Pentax Medical.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
11
Study locations

Study Summary

To evaluate the efficacy and safety of the CryoBalloon Focal Ablation System for the treatment of previously-untreated ("treatment naïve") Barrett's Esophagus (BE)

Conditions Studied

Interventions

  • DEVICE CryoBalloon Ablation System

Study Locations (11)

New York

  • Northwell Health - Manhasset
  • New York Presbyterian Hospital-Columbia University Medical Center - New York

Pennsylvania

  • Geisinger Medical Center - Danville
  • Thomas Jefferson University - Philadelphia

California

  • UC Irvine - Orange

Florida

  • Sarasota Memorial Hospital - Sarasota

Illinois

  • University of Chicago - Chicago

Maryland

  • John Hopkins - Baltimore

Minnesota

  • Mayo Clinic - Rochester

North Carolina

  • University of North Carolina School of Medicine - Chapel Hill

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2016-03
Est. Completion 2025-12
Phase NA
Pentax Medical

4 total trials

What the registry record for NCT02514525 still lists

NCT02514525 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 3,561-participant average among 32 other Barrett Esophagus trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Barrett Esophagus appearing as the primary indexed condition, and to 1 intervention - of which CryoBalloon Ablation System is the first listed.

NCT02514525 lists 11 locations in 9 states (New York, Pennsylvania, California).

Frequently Asked Questions

What is clinical trial NCT02514525 about?

NCT02514525 is a clinical study titled "Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System". To evaluate the efficacy and safety of the CryoBalloon Focal Ablation System for the treatment of previously-untreated ("treatment naïve") Barrett's Esophagus (BE)

What is the current status of trial NCT02514525?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2016-03. Estimated completion is 2025-12.

What conditions does trial NCT02514525 study?

This clinical trial studies the following conditions: Barrett Esophagus.

What interventions are being tested in trial NCT02514525?

The interventions under investigation include: CryoBalloon Ablation System (DEVICE).

Who is sponsoring clinical trial NCT02514525?

This trial is sponsored by Pentax Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02514525 being conducted?

This trial has 11 study locations across California, Florida, Illinois, Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Barrett Esophagus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02514525's enrollment target sits among peer trials

150 19th of 32 higher than 14 of 32 other Barrett Esophagus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Barrett Esophagus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02514525, the US trial registry maintained by the National Library of Medicine. NCT02514525 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.